Glatiramer clinical trials
Also written Copaxone.
How each study uses glatiramer is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 20 Dec 1996 · COPAXONE · NDA 020622 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2006 (5)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1994 | 1 |
| 2003 | 4 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 18
Teva Branded Pharmaceutical Products R&D, Inc. (12) · Teva Neuroscience, Inc. (2) · Sanofi (2) · Sheba Medical Center (2) · The Cleveland Clinic (1) · University of Kansas Medical Center (1) · Hadassah Medical Organization (1) · Teva Pharmaceutical Industries, Ltd. (1)
Often tested with
Tested in the same studies.
Interferon beta-1a (3) · Natalizumab (2) · Methylprednisolone (2) · Interferon beta-1b (1) · Rituximab (1) · Teriflunomide (1) · Acetylcysteine (1) · Alemtuzumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test glatiramer.
- Jul 2027Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPhase 4 · The Cleveland Clinic
Studies
Open first, then newest update. How each study uses glatiramer is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSActive, not recruitingPhase 4The Cleveland ClinicNCT03535298Written as Escalation Therapies Group
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminatedPhase 3Genzyme, a Sanofi CompanyNCT03368664Written as Glatiramer acetate
- Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart FailureCompletedPhase 2Hadassah Medical OrganizationNCT06003972Written as Copaxone
- A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible TumorsActive, not recruitingPhase 1University of Kansas Medical CenterNCT03982212Written as Copaxone
- Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Teva Pharmaceutical Industries, Ltd.NCT00326625Written as 40 mg glatiramer acetate
- Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®CompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT02499900Written as Copaxone®
- A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01067521Written as Glatiramer acetate (GA)
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRICompletedPhase 4University of Medicine and Dentistry of New JerseyNCT00176592Written as Copaxone
- Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisCompletedPhase 3BiocadNCT02753088Written as BCD-063
- Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)CompletedNot applicableUniversity at BuffaloNCT00937157Written as Copaxone
- Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessCompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT00203021Written as Glatiramer acetate
- Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsCompletedPhase 2/3Isfahan University of Medical SciencesNCT03315923Written as Glatiramer Acetate
- Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)CompletedPhase 2Montefiore Medical CenterNCT02153723Written as Glatiramer Acetate
- High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple SclerosisWithdrawnPhase 2Johns Hopkins UniversityNCT00939549Written as Cyclophosphamide/Glatiramer acetate
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00856635Written as Glatiramer Acetate
- A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®CompletedPhase 4Teva Neuroscience, Inc.NCT00239993Written as glatiramer acetate
- Efficacy and Safety of GTR in Comparison to Copaxone®CompletedPhase 3Synthon BVNCT01489254Written as Glatiramer Acetate (GTR)
- Safety and Tolerability of Glatiramer AcetateCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01874145Written as GA 20 mg/mL
- Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxCompletedPhase 3Fred LublinNCT00211887Written as glatiramer acetate
- An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01578785Written as Glatiramer Acetate
See all 39 studies that test glatiramer →
Given beside what is tested · 6 — glatiramer is usual care or a partner of the new treatment
- Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)WithdrawnPhase 2BiogenNCT04079088Written as Glatiramer acetate
- Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetateCompletedPhase 2University of Colorado, DenverNCT01569451Written as Glatiramer Acetate
- Treatment of Multiple Sclerosis With Copaxone and AlbuterolCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00039988Written as Glatiramer acetate
- A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)CompletedPhase 2University of California, Los AngelesNCT00451204Written as Copaxone
- Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer AcetateTerminatedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT00203047Written as Glatiramer Acetate
- Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple SclerosisCompletedPhase 2SanofiNCT00475865Written as Glatiramer Acetate (GA)
As the comparator · 10 — what is tested is compared with glatiramer
- MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneTerminatedPhase 3Novartis PharmaceuticalsNCT01633112Written as glatiramer acetate
- Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedPhase 4EMD SeronoNCT00078338Written as Copaxone®
- Safety of New Formulation of Glatiramer AcetateCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00947752Written as Glatiramer Acetate
- Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedPhase 2EMD SeronoNCT01963611Written as Copaxone 20 mg
- Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisCompletedPhase 3BiogenNCT00451451Written as Glatiramer Acetate
- Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedPhase 3BiogenNCT01058005Written as glatiramer acetate
- Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)CompletedPhase 4Novartis PharmaceuticalsNCT01534182Written as Glatiramer acetate (GA)
- Safety and Efficacy Study of Copaxone Administered in Combination With MinocyclineCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT00203112Written as glatiramer acetate with minocycline
- A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.CompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT00240032Written as glatiramer acetate injection with oral cetirizine hydrochloride
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsCompletedPhase 3BayerNCT00099502Written as Copaxone
Codes
What other systems call glatiramer · ClinicalTrials.gg INT006532
- MeSH (NLM) D000068717Glatiramer AcetateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U782C039QPGLATIRAMERConfirmed FDA, NLM
- RxNorm 214582One source FDA
- NCI Thesaurus C87680GlatiramerOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068717 | Glatiramer Acetate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U782C039QP | GLATIRAMER | Confirmed FDA, NLM |
| RxNorm | 214582 | — | One source FDA |
| NCI Thesaurus | C87680 | Glatiramer | One source FDA |
Also registered as glatiramer acetate (UNII 5M691HL4BO · RxNorm 84375).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.